A new approach to the development of anti-ischemic drugs. Substances that counteract the deleterious effect of lysophosphatidylcholine on the heart

Japanese Heart Journal

Volumn 38, Issue 1, 1997, Pages 11-25

  Hashizume, Hiroko ^a   Ehsanul Hoque, A N ^b   Magishi, Katsuaki ^a   Hara, Akiyoshi ^a   Abiko, Yasushi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Anti ischemic drugs; Free fatty acid; Ischemia reperfusion; Lysophosphatidylcholine

Indexed keywords

ANTIANGINA PECTORIS AGENT; CALCIUM ION; FATTY ACID; LYSOPHOSPHATIDYLCHOLINE; MEMBRANE PHOSPHOLIPID; PHOSPHOLIPASE A2;

ARTICLE; CALCIUM CELL LEVEL; ENZYME ACTIVATION; HEART; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 1842412462     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.38.11     Document Type: Article

References (52)

1. Post JA, Langer GA, Op den Kamp JAF, Verkleij AJ. Phospholipid asymmetry in cardiac sarcolemma: Analysis of intact cells and 'gas-dissected' membranes. Biochim Biophys Acta 1988; 943: 256- 66.
2. Das DK, Engelman RM, Rousou JA, Breyer RH, Otani H, Lemeshow S. Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion. Am J Physiol 1986; 251 (Heart Circ Physiol 20): H71-9.
3. Shaikh NA, Downer E. Time course of changes in porcine myocardial phospholipid levels during ischemia. Circ Res 1981; 49: 316-25.
4. Corr PB, Snyder DW, Lee BI, Gross RW, Keim C, Sobel B. Pathophysiological concentrations of lysophosphatides and the slow response. Am J Physiol 1982; 243 (Heart Circ Physiol 12): H187-95.
5. 2+ accumulation in rat cardiac myocytes. Am J Physiol 1983; 244 (Heart Circ Physiol 13): H32-8.
6. 2+-overload in isolated cardiomyocytes and effect of cytoprotective drugs. J Mol Cell Cardiol 1992; 24: 977-88.
7. Otani H, Prasad MR, Jones RM, Das DK. Mechanism of membrane phospholipid degradation in ischemic-reperfused rat hearts. Am J Physiol 1989; 257 (Heart Circ Physiol 26): H252-8.
8. Sedlis SP, Sequeira JM, Altszuler HM. Coronary sinus lysophosphatidylcholine accumulation during rapid atrial pacing. Am J Cardiol 1990; 66: 695-8.
9. Corr PB, Cain ME, Witkowski FX, Price DA, Sobel BE. Potential arrythmogenic electrophysiological derangements in canine purkinje fibers induced by lysophosphoglyderides. Circ Res 1979; 44: 822-32.
10. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol 1991; 23 (Supp I): 11-22.
11. Man RYK, Kinnaira AAA, Bihler I, Choy PC. The association of lysophosphatidylcholine with isolated cardiac myocytes. Lipids 1990; 25: 450-4.
12. Sedlis SP, Sequeira JM, Ahumada GG, Sherif NE. Effects of lysophosphatidylcholine on cultured heart cells: Correlation of rate of uptake and extent of accumulation with cell injury. J Lab Clin Med 1988; 112: 745-54.
13. Fink KL, Gross RW. Modulation of canine myocardial sarcolemmal membrane fluidity by amphiphilic compounds. Circ Res 1984; 55: 585-94.
14. + ATPase. Am J Physiol 1984; 247 (Heart Circ Physiol 16): H840-6.
15. Oishi K, Zheng B, Kuo JF. Inhibition of Na, K-ATPase and sodium pump by protein kinase C regulators sphingosine, lysophosphatidylcholine, and oleic acid. J Biol Chem 1990; 265: 70-5.
16. Burnashev NA, Undrovinas AI, Fleidervish LA, Makielski JC, Rosenshtraukh LV. Modulation of cardiac sodium channel gating by lysophosphatidylcholine. J Mol Cell Cardiol 1991; 23 (Supp I): 23-30.
17. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 1992; 71: 1231-41.
18. Magishi K, Kimura J, Kubo Y, Abiko Y. Exogenous lysophosphatidyl-choline increases non-selective cation current in guinea-pig ventricular myocytes. Pflügers Archiv: Eur J Physiol 1996; 432: 345-50.
19. Hoque ANE, Hoque N, Hashizume H, Abiko Y. A study of dilazep: II. Dilazep attenuates lysophosphatidylcholine-induced mechanical and metabolic derangements in the isolated, working rat heart. Jpn J Pharmacol 1995; 67: 233-41.
20. Woodley SL, Ikenouchi H, Barry WH. Lysophosphatidylcholine increases cytosolic calcium in ventricular myocytes by direct action on the sarcolemma. J Mol Cell Cardiol 1991; 23: 67-80.
21. Boime I, Smith EE, Hunter FE Jr. The role of fatty acids in mitochondrial changes during liver ischemia. Arch Biochem Biophys 1970; 139: 425-43.
22. Witter RF, Morrison A, Shepardson GR. Effect of lysolecithin on oxidative phosphorylation. Biochem. Biophys Acta 1957; 26: 120-9.
23. Hoque ANE, Hoque N, Hashizume H, Abiko Y. Dilazep and d-propranolol attenuate mitochondrial damage induced by lysophosphatidylcholine. Folia Pharmacol Japon 1995; 105: 8P (abstract in Japa- nese).
24. Hashizume H, Abiko Y. Dilazep and d-propranolol attenuate calcium overload induced by lysophosphatidylcholine in cardiac myocytes. Clin Exp Cardiol 1996; 1: 45-8.
25. 2 activity. Basic Res Cardiol 1987; 82 (Supp 1): 127-35.
26. Magishi K, Yazawa K, Abiko Y. Effect of lysophosphatidylcholine and pH on the calcium current in guinea-pig ventricular myocytes. Folia Pharmacol Japon 1995; 105: 5P (abstract in Japanese).
27. Ver Donck L, Borgers M, Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle. Cardiovasc. Res. 1993; 27: 349-57.
28. Weltzien HU. Cytolytic and membrane-perturbing properties of lysophosphatidylcholine. Biochim Biophys Acta 1979; 559: 259-87.
29. Hashizume H, Abiko Y. Calcium overload induced by lysophosphatidyl-choline in isolated rat cardiac myocytes. J Mol Cell Cardiol 1995; 27: A201 (abstract).
30. Sargent CA, Vesterqvist O, Ogletree ML, Grover GJ. Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat hearts. J Mol Cell Cardiol 1993; 25: 905-13.
31. Bersohn MM, Philipson KD, Weiss RS. Lysophosphatidylcholine and sodium-calcium exchange in cardiac sarcolemma: comparison with ischemia. Am J Physiol 1991; 260 (Cell Physiol 29): C433-8.
32. Sedlis SP, Sequeira JM, Altszuler HM. Potentiation of the depressant effects of lysophosphatidylcholine on contractile properties of cultured cardiac myocytes by acidosis and superoxide radical. J Lab Clin Med 1990; 115: 203-16.
33. Sasaki Y, Asaoka Y, Nishizuka Y. Potentiation of diacylglycerol-induced activation of protein kinase C by lysophospholipids. Subspecies difference. FEBS letters 1993; 320: 47-51.
34. Oishi K, Raynor RL, Charp PA, Kuo JF. Regulation of protein kinase C by lysophospholipids. Potential role in signal traduction. J Biol Chem 1988; 263: 6865-71.
35. 2 in signal transduction through protein kinase C. Proc Nad Acad Sci USA 1992; 89: 6447-51.
36. Kugiyama K, Ohgushi M, Sugiyama S, et al. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res 1992; 71: 1422-28.
37. Ohgushi M, Kugiyama K, Fukunaga K, et al. Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler Thromb 1993; 13: 1525- 32.
38. Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K, Yasue H. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ Res 1994; 74: 565-75.
39. Daugherty A, Roselaar SE. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc Res 1995; 29: 297-311.
40. + exchange. J Mol Cell Cardiol 1988; 20: 493-500.
41. Hoque ANE, Nasa Y, Abiko Y. Cardioprotective effect of d-propranolol in ischemic-reperfused isolated rat hearts. Eur J Pharmacol 1993; 236: 269-77.
42. Nasa Y, Ichihara K, Abiko Y. Both d-cis- and l-cis-diltiazem have anti-ischemic action in the isolated, perfused working rat heart. J Pharmacol Exp Ther 1990; 255: 680-9.
43. Hoque ANE, Hashizume H, Abiko Y. A study on dilazep: I. Mechanism of anti-ischemic action of dilazep is not coronary vasodilation but decreased cardiac mechanical function in the isolated, working rat heart. Jpn J Pharmacol 1995; 67: 225-32.
44. Chiba K, Hashizume H, Inagagi S-I, Abiko Y. Dilazep inhibits binding of Batrachotoxin to sodium channels in canine sarcolemmal vesicles. Arch Int Pharmacodyn 1995; 330: 138-50.
45. Hashizume H, Akiyama K, Abiko Y. Effects of antiischemic drugs on veratridine-induced hypercontracture in rat cardiac myocytes. Eur J Pharmacol 1994; 271: 1-8.
46. 2+-overload induced by lysophosphatidylcholine in isolated rat cardiomyocytes. Br J Pharmacol 1996; 118: 865-70.
47. Mustafa SJ. Effects of coronary vasodilator drugs on the uptake and release of adenosine in cardiac cells. Biochem Pharmacol 1979; 28: 2617-24.
48. Hara A, Akahira M, Abiko Y. Effect of K-7259, a novel derivative of dilazep, on cardiovascular actions of adenosine: Comparison with dilazep. Arch Int Pharmacodyn 1995; 330: 66-75.
49. Hoque ANE, Hoque N, Hashizume H, Abiko Y. Cardioprotective effect of K-7259, a new dilazep derivative, in the ischemic-reperfused working rat hearts. Jpn J Pharmacol 1995; 67 (Suppl. I): 121P (abstract).
50. Hara A, Abiko Y. Protective effects of dilazep and its novel derivative, K-7259, on mechanical and metabolic derangements induced by hydrogen peroxide in the isolated perfused rat heart. J Pharmacol Exp Ther 1996; 277: 565-71.
51. 2-induced cell damage. J Pharmacol Exp Ther 1996; 277: 207-11.
52. Cruickshank JM, Prichard BNC. Beta-blockers in Clinical Practice, Churchill Livingstone, Edinburgh, 1987.